Republicans in Congress are trying to attract more people to direct-to-consumer drug purchases on platforms like TrumpRx by requiring insurers to count that spending toward patients' deductibles and out-of-pocket limits.
Why it matters: Paying cash for drugs has limited appeal for insured patients, in part because it doesn't help them get to the point where insurance picks up a bigger portion of their health costs.
The threat of new tariffs on drugmakers has set off a debate within the biotech industry over whether to cut voluntary pricing deals with the Trump administration in exchange for exemptions.
Why it matters: Small and midsize companies don't have the resources of a Pfizer or Merck to make price cuts, domestic manufacturing investments and other concessions the White House is seeking.
